Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | IAPP | P10997 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26140303 | 0.84 | GRM5 (0.40) | GRM5MRGPRX4MAPK1PTGER4CYP1A2 | |
| SCHEMBL19915961 | 0.73 | S1PR4 (0.61) | S1PR4GRM5NPSR1KMT2AKDM4E | |
| SCHEMBL6509581 | 0.73 | KDM4E (0.50) | GRM5MRGPRX4MAPK1PTGER4NPSR1 | |
| SCHEMBL2490015 | 0.72 | KMT2A (0.45) | S1PR4GRM5MAPK1NPSR1KMT2A | |
| SCHEMBL2486981 | 0.72 | KMT2A (0.45) | S1PR4GRM5MAPK1NPSR1KMT2A | |
| SCHEMBL31620653 | 0.72 | GRM5 (0.49) | GRM5MRGPRX4MAPK1PTGER4CYP1A2 | |
| SCHEMBL30503268 | 0.71 | S1PR4 (0.43) | S1PR4NPSR1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL15402088 | 0.71 | S1PR4 (0.43) | S1PR4NPSR1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL16742565 | 0.71 | MRGPRX4 (0.44) | S1PR4MRGPRX4MAPK1IAPP | |
| SCHEMBL17513664 | 0.70 | KMT2A (0.39) | S1PR4GRM5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | ADORA2A, ADORA2B, ADORA3 | S1PR4 342/4885GRM5 894/4885MRGPRX4 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.